ELV Stock Forecast & Price Target

Elevance Health's membership has increased approximately 10% year-over-year, bolstered by growth in new markets and strategic positioning as the largest provider of Blue Cross Blue Shield coverage across 14 states. The company anticipates a Medicare Advantage margin improvement of at least 2% in 2026, driven by a favorable membership mix and pricing strategies, alongside strong performance in the Commercial ASO segment supported by robust retention and new client acquisitions. Furthermore, Elevance's diversified growth opportunities, alongside favorable margin trends in Medicaid and continued expansion into pharmacy benefit management, underpin a positive outlook for the company's financial performance.

Elevance Health is facing significant challenges that contribute to a negative outlook, including a projected deterioration in Medicaid margins of approximately 100 basis points for the second half of 2025, coupled with anticipated headwinds of around $2.50 on a year-over-year basis for Medicaid in 2026. The company's guidance indicates a decline in commercial risk membership by high single digits, primarily due to deliberate pricing strategies leading to attrition and expected reductions in Medicaid membership by roughly 9% year-over-year, further compounding revenue pressures. Additionally, while Elevance anticipates some earnings growth from certain segments, the overall financial context reflects a downward adjustment of 2026 EPS estimates, now lowered to $25.54 from $26.70, signaling a conservative outlook on the company’s earnings potential moving forward.